Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Effect of Ozempic on Diabetic Nephropathy: A Case Report.

Joseph J

Cureus7 Jul 2025

PMID40772213 (opens in a new tab)PMCIDPMC12326341 (opens in a new tab)DOI10.7759/cureus.87416 (opens in a new tab)PepBankPUB-40772213
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Semaglutide (Ozempic), a Glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in improving glycemic control and offering renal protection in type 2 diabetes. We present the case of a 40-year-old male with poorly controlled type 2 diabetes and early diabetic nephropathy, who experienced significant metabolic and renal improvements following semaglutide therapy. Initially, on SGLT2 inhibitors, the patient discontinued treatment due to recurrent urinary tract infections. On presentation, he exhibited hyperglycemia, dyslipidemia, proteinuria, and reduced eGFR. Semaglutide was initiated alongside metformin, gliclazide, antihypertensives, and lipid-lowering agents. Over 12 months, HbA1c improved from 9.8% to 6.1%, and urine albumin-to-creatinine ratio decreased from 267 mg/g to 34 mg/g, with improved eGFR. This case supports the renoprotective and metabolic benefits of semaglutide and highlights its potential as a therapeutic option in patients intolerant to SGLT2 inhibitors.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 40-year-old man with poorly controlled type 2 diabetes and early nephropathy, HbA1c fell from 9.8% to 6.1% over 12 months of semaglutide, given with background diabetes and heart medicines.

    In plain wordsIn one man with type 2 diabetes, HbA1c fell a lot over 12 months on semaglutide, which he took with other medicines.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change over 12 months
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c
    9.8%
    baseline
    HbA1c
    6.1%
    12 months

    Source sentences

    Summary
    Over 12 months, HbA1c improved from 9.8% to 6.1%
    2 context sentences
    Summary · context
    Semaglutide was initiated alongside metformin, gliclazide, antihypertensives, and lipid-lowering agents.
    Summary · context
    We present the case of a 40-year-old male with poorly controlled type 2 diabetes and early diabetic nephropathy, who experienced significant metabolic and renal improvements following semaglutide therapy.
  2. 02HumanCase report or seriesEfficacy outcome

    In the same patient, the urine albumin-to-creatinine ratio fell from 267 mg/g to 34 mg/g over 12 months, with other medicines also given.

    In plain wordsIn this man, a kidney damage marker in urine fell a lot over 12 months on semaglutide, which he took with other medicines.

    Peptide
    Semaglutide
    Outcome
    DecreaseUrine albumin-to-creatinine ratio change over 12 months
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Urine albumin-to-creatinine ratio
    267 mg/g
    baseline
    Urine albumin-to-creatinine ratio
    34 mg/g
    12 months

    Source sentences

    Summary
    urine albumin-to-creatinine ratio decreased from 267 mg/g to 34 mg/g, with improved eGFR.
    2 context sentences
    Summary · context
    Semaglutide was initiated alongside metformin, gliclazide, antihypertensives, and lipid-lowering agents.
    Summary · context
    We present the case of a 40-year-old male with poorly controlled type 2 diabetes and early diabetic nephropathy, who experienced significant metabolic and renal improvements following semaglutide therapy.
  3. 03HumanCase report or seriesEfficacy outcome

    In the same patient, eGFR improved over 12 months of semaglutide, given with background medicines.

    In plain wordsIn this man, a kidney filtering measure improved over 12 months on semaglutide, which he took with other medicines.

    Peptide
    Semaglutide
    Outcome
    IncreaseeGFR change over 12 months
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    with improved eGFR.
    2 context sentences
    Summary · context
    On presentation, he exhibited hyperglycemia, dyslipidemia, proteinuria, and reduced eGFR.
    Summary · context
    We present the case of a 40-year-old male with poorly controlled type 2 diabetes and early diabetic nephropathy, who experienced significant metabolic and renal improvements following semaglutide therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.